Tamoxifen does not appear to have beneficial effects on bone loss in breast cancer patients who have undergone menopause due to adjuvant chemotherapy.
Results of a randomized double blind National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) MA12 study were presented December 12 by study author Katia S. Tonkin, MD, Cross Cancer Institute, Edmonton, Alberta, Canada, at the 25th annual San Antonio Breast Cancer Symposium in San Antonio, Texas.
Designed to look at the potential role of tamoxifen in the prevention of bone loss in women rendered postmenopausal by chemotherapy, the study enrolled pre/peri-menopausal high risk node negative and node positive women with a mean age of 46.5 years.
Patients were treated with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or with cyclophosphamide, epirubicin, and 5-fluorouracil (CEF) and were randomized to either tamoxifen or placebo. Forty-one patients were entered into the study and 34 were evaluable.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!